<DOC>
	<DOCNO>NCT03055078</DOCNO>
	<brief_summary>This study evaluate safety efficacy Umbilical Cord Derived Mesenchymal Stem Cells transplantation aplastic anemia .</brief_summary>
	<brief_title>Umbilical Cord Derived Mesenchymal Stem Cells Therapy Aplastic Anemia</brief_title>
	<detailed_description>Aplastic anemia ( AA ) disorder think cause immune-mediated bone marrow failure . Not people AA eligible today 's standard treatment . One new treatment approach use umbilical cord derive mesenchymal stem cells—specialized cell capable develop type cells—to provide basis clinical application . The aim present study investigate safety efficacy vein infusion allogeneic mesenchymal stem cell patient AA .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>1 . Diagnosis AA accord establish criterion 2010 2 . Age 14 60 year 3 . Suffering AA within six month 4 . No serious infection acute hemorrhage . 5 . Left ventricular ejection fraction ( LVEF ) ≥ 50 % 6 . No acute infectious disease . 7 . Understanding willingness sign write informed consent document . 8 . Eastern Cooperative Oncology Group ( ECOG ) score 02pionts . Patients AA disqualify study follow applicable . 1 . Severe aplastic anemia ( SAA ) severe infection . 2 . Severe aplastic anemia ( SAA ) active hemorrhage . 3 . Severe heart attack , liver kidney disease follow serious complication 4 . Patients allergic constitution . 5 . Pregnancy lactation . 6 . Accompanied malignant tumor clonal disease . 7 . Patients active tuberculosis , acute sever hepatitis infectious period disease .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>